

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) Russel T. Jordan Serial No. 09/021,421 Filed February 10, 1998 For Chelated 8-Hydroxyquinoline and Use Thereof in a Method of Treating Epithelial Lesions		Examiner James D. Anderson Group Art No. 1614 Confirmation No. 4431
---	--	---

September 23, 2010

Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT TRANSMITTAL**

Dear Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.97(b), or  
(Within three months of filing national application, or date of entry of national application, or before mailing date of first office action on the merits, whichever occurs last)
- ☐ under 37 CFR 1.97(c) together with either a:  
☐ Statement under 37 CFR 1.97(e), or  
☐ a \$180 fee under 37 CFR 1.17(p), or  
(After the CFR 1.97(b) time period, but before final action or notice of allowance, which ever occurs first)
- ☒ under 37 CFR 1.97(d) together with a:  
☒ Statement under 37 CFR 1.97(e)(1) or (2), and  
☒ a \$180.00 fee set forth in 37 CFR 1.17(p).  
(Filed after final action, a notice of allowance, on or before payment of issue fee)

Please charge to Deposit Account 12-0600 the sum of \$180.00. At any time during the pendency of this application, please charge any fees required or credit any overpayment to Deposit Account 12-0600 pursuant to 37 CFR 1.25.

Applicant(s) submit herewith Form PTO 1449 – Information Disclosure Statement together with copies of non-U.S. patents, publications or other information (if any) of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of the application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

**Statement Under 37 CFR 1.97(e) –**

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign

application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).


The below-listed reference disclosed in form PTO 1449 submitted herewith is to prosecution (i.e., an Office Action, Response, etc.) from a patent application related to the current application and/or subject matter set forth therein. This prosecution reference is provided to meet the Duty of Disclosure as specifically set forth at MPEP 2001.06 and interpreted by the Federal Circuit in McKesson Information Solutions, Inc. v. Bridge Medical, Inc., 487 F.3d 897 (Fed. Cir. 2007). A copy of each prosecution reference, or an English language translation/summary for foreign prosecution, is submitted herewith.

1. Office Action dated June 23, 2010 issued in related U.S. Patent Application Serial No. 11/434,613, 10 pages

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

LATHROP & GAGE LLP



Dan Cleveland, Jr., Reg. No. 36,106  
4845 Pearl East Circle, Suite 201  
Boulder, Colorado 80301  
Telephone: (720) 931.3012  
Facsimile: (720) 931.3001